Sign in
Taking people in United StatesPhase 2

Cannabidiol and THC for knee osteoarthritis pain

Tests cannabidiol, THC, or both on pain in people with knee osteoarthritis.

Key facts

Who runs it
Steven E Harte, PhD
Where
Ann Arbor, United StatesSee the site
Trial code
Registry title
Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee
Status
Recruiting
Phase
Phase 2
People taking part
200 people, planned
Started
22 Feb 2022
Expected to end
30 Jun 2027
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Placebo
  • Cannabidiol (CBD)
  • Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)
Record updated
4 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with knee osteoarthritis and long-lasting knee pain. It tests THC, CBD, both together, or placebo.

Age
21 Years to 75 Years
Sex
All sexes can join.
Disease stage
Osteoarthritis of the knee diagnosed by a medical provider. Moderate to severe knee pain for 6 months or more.
Earlier treatment
No cannabis or CBD in the month before joining. No previous total knee replacement. No current opioid use (tramadol is allowed). No current valproate, clobazam or warfarin.

Main reasons for not taking part

  • Past knee replacement, or one planned during the study
  • Pregnant or breastfeeding
  • Liver failure, cirrhosis, hepatitis or high liver blood tests
  • Severe heart disease, epilepsy or seizures, head injury, or peripheral neuropathy
  • Cannot have an MRI scan (for example metal implants or severe fear of closed spaces)

The registry criteria, word for word

Show all 43 criteriaShow less

Who can take part

  • Ability to read and speak English to allow for written informed consent, phenotyping, and patient-reported outcomes measures
  • Willingness to participate in a drug intervention trial
  • Diagnosis of osteoarthritis (OA) of the knee by a medical provider (confirmed by checking medical records)
  • Chronic knee pain, defined as moderate to severe knee pain for ≥ 6-month duration
  • No use of cannabis or CBD in the past in the month prior to study enrollment as per self-report
  • Fibromyalgia (FM) Survey Criteria score available. The questionnaire will be assessed by the research team for scoring. We will recruit enough patients to satisfy the spectrum of FM scores in four quartiles based on our previously existing data. Once a quartile is filled (approximately 40 patients enrolled), then we will not include more people from that quartile
  • Self-reported normal visual acuity or correctable (with corrective lenses- glasses or contacts) to at least 20/40 for reading instructions in the MRI and visual sensitivity testing
  • No contraindications to magnetic resonance imaging (MRI) (for example (e.g.), metal implants)
  • Able to lie still on their back for 1-1.5 hours during MRI
  • Willingness to refrain from pain medications such as non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen for 12 hours prior to neuroimaging and Quantitative Sensory Testing (QST)
  • Willingness to refrain from alcohol and nicotine before QST and neuroimaging (alcohol and nicotine consumption is allowed after testing is completed)
  • Willingness to refrain from physical activity or exercise that would cause significant muscle and/or joint soreness for 48 hours prior to testing (routine exercise or activity that does not lead to soreness is acceptable)
  • Willingness to maintain a stable treatment regimen for chronic knee OA pain during the clinical trial (e.g., not initiating a new course of physical therapy)
  • No use of adjunctive pain medications or stable chronic daily use of adjunctive pain medications (excluding opioids)
  • Willingness to avoid grapefruit juice or food products for the duration of the study
  • Females of reproductive potential must agree to use acceptable birth control from the screening visit and until the completion study drug administration. Sexually active male participants and/or their female partners must agree to use effective contraception during study drug treatment of the male participant. Male participants may also agree not to donate sperm during study drug treatment

Who cannot take part

  • Previous total knee arthroplasty
  • Use of cannabis or CBD in the past month per self-report and/or drug screen
  • Current opioid use (excepting tramadol) per self-report and/or drug screen
  • Current use of moderate or strong inhibitors of cytochrome p450 (CYP) enzymes CYP3A4 and CYP2C19, strong inducers of CYP3A4 or CYP2C19, moderate or strong inhibitors/inducers of CYP2C9, and narrow therapeutic index drugs (e.g., cyclosporine, amphotericin B). Participants will also not be allowed to start using these drugs during the study period if they wish to stay in the study
  • Severe physical impairment (e.g., blindness, deafness, paraplegia)
  • Co-morbid medical conditions that may significantly impair physical functional status (e.g., history of non-skin malignancy, or autoimmune disorder)
  • Self-reported allergies to sesame oil or cannabis/cannabinoids
  • Self-reported medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., schizophrenia, malignancy, psychosis, suicidal ideation, history of substance abuse; note that stable anxiety and depression are not exclusions)
  • Liver failure
  • Active diagnosis or current symptoms of hepatitis by self-report
  • Self-reported uncontrolled diabetes
  • Resting heart rate at screening less than 50 beats per minute (bpm) or greater than 100 bpm
  • Severe cardiovascular disease (examples: history of myocardial infarction, unstable angina, severe coronary artery disease, congestive heart failure, or severe valvular abnormalities) that is self-reported by patient or by medical record
  • Diagnosed or self-reported epilepsy or history of seizures
  • Current head injury or history of head injury (e.g., traumatic brain injury)
  • Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol
  • Elevated liver enzymes and bilirubin (measured via blood test at screening):; Serum total bilirubin ≥ 2.5 milligrams per deciliter (mg/dL); or,; Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥ 3x upper limit normal (ULN); or,; Alkaline phosphatase ≥ 2 times ULN
  • Individuals who are actively applying for or in litigation for compensation or disability and other aspects associated with potential secondary gain per self-report
  • Inability to provide written informed consent
  • Planned total knee arthroplasty within the time frame of the study
  • Current valproate, clobazam, or warfarin use per self-report or medical records
  • Pregnant or nursing
  • Self-reported liver cirrhosis
  • Blood pressure at screening above 180 systolic and/or 120 diastolic
  • Severe claustrophobia precluding MRI
  • Unable to fit in or lie comfortably in MRI
  • Diagnosed peripheral neuropathy

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 21 and 75 years old?

Where in United States

  • University of MichiganAnn Arbor, United StatesContact: Katherine ScottTaking people

About the trial

What the trial wants to find out

This clinical trial is being done to better understand how daily treatment with Tetrahydrocannabinol (THC), Cannabidiol (CBD), or the combination of CBD plus THC affects knee osteoarthritis pain and other related symptoms.

Read full original descriptionShow less

Consented participants will have a screening period and visit (up to 30 days to treatment start). If participants pass the screening phase, they will be randomly assigned to take one of the investigational study drugs. For this study, participants will not know when or if they are taking CBD, THC, THC plus CBD, and when or if taking placebo.

Clinical pain will be assessed at multiple times throughout the study, and eligibility will be re-assessed at two weeks into the treatment period. It is possible that subjects will not be able to participate in the study after 14 days of of treatment. The treatment period will take approximately 16 weeks and then a follow-up period for approximately 2 weeks. In addition to treatment, participants will have clinical assessments, blood draws, questionnaires, daily pain diaries, sensory testing, as well as have functional connectivity magnetic resonance imaging (fcMRI).

The 4 groups in the trial

  • PlaceboPlacebo, for comparison
  • Cannabidiol (CBD)Treatment being tested

    Up to 150 mg/day.

  • Tetrahydrocannabinol (THC)Treatment being tested

    Up to 10 mg/day.

    Treatment: Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)

  • CBD plus THCTreatment being tested

    Up to 150 mg/day CBD plus up to 10 mg/day THC.

    Treatment: Cannabidiol (CBD) and Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee
Plain-language title
Cannabidiol and THC for knee osteoarthritis painGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT04992624, who can take part
Record updated
4 September 2026